Sanofi Profit Beats Estimates as Dupixent Sales Rise 31%
Sanofi reported better-than-expected first-quarter profit, with earnings per share of €1.88 topping the €1.78 consensus as Dupixent sales climbed 31% to €4.2 billion.
The company maintained its full-year outlook for high single-digit sales growth. The result is a boost for incoming CEO Belén Garijo as she prepares to take over this month and faces the challenge of rejuvenating Sanofi’s pipeline of new medicines, while the CFO said Middle East tensions could moderately affect 2026 sales growth and are factored into guidance.
From the sources (4 posts)
@businessSanofi reported better-than-expected profit in a boost for incoming CEO Belén Garijo as she confronts the challenge of rejuvenating the drugmaker’s pipeline of new medicines
@firstsquawkSanofi’s CFO acknowledges setbacks last year, adding that such occurrences are typical in the sector
@firstsquawkSanofi’s CFO: Middle East tensions could moderately affect 2026 sales growth and are factored into guidance
@wallstengineSanofi $SNY posted Q1 EPS of €1.88, ahead of the €1.78 consensus, as Dupixent sales rose 31% to €4.2B. The company kept its full-year outlook for high single-digit sales growth as incoming CEO Belén Garijo prepares to take over this month.